Sanofi (SNY)
Pre-Market:
| Previous Close | 47.15 |
| Open | 47.07 |
| Bid | 47.68 x 200 |
| Ask | 47.72 x 200 |
| Day's Range | 47.00 - 48.30 |
| 52 Week Range | 42.63 - 57.82 |
| Volume | |
| Avg. Volume | 1,949,198 |
| Market Cap | 119.056B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 20.83 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.04 (4.27%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | N/A |
- Bloomberg
Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Speeds Cheaper EV Plans, Calming Fears Over StrategyBillionaire Pinaults Fight to Pull Gucci Off the Discount RackR
- Zacks
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
- Reuters
Sanofi to overhaul US operations of vaccines, cut jobs
Sanofi would implement a "streamlined strategic sales structure" to better support its customers and patients, it said without disclosing any details on the changes to be made, the timeframe and the number of employees to be impacted. Sanofi CEO Paul Hudson has been trying to build investor confidence in the company's drug pipeline since he unexpectedly abandoned 2025 margin targets last October to instead boost drug development spending. The company's vaccine portfolio includes preventive shots for a common respiratory infection in infants, influenza vaccines, COVID vaccines and vaccines for infections like meningitis and tetanus.
